DDInter1763 DDInter1658
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Temsirolimus {u} (Compound) treats {v} (Disease) kidney cancer
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
Temsirolimus {u} (Compound) upregulates {v} (Gene) MICU1
Temsirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Temsirolimus {u} (Compound) downregulates {v} (Gene) TFDP1
Temsirolimus {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Temsirolimus (Compound) resembles Everolimus (Compound)
Temsirolimus (Compound) treats kidney cancer (Disease)
Temsirolimus (Compound) binds CYP3A4 (Gene)
Temsirolimus (Compound) upregulates MICU1 (Gene)
Temsirolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Temsirolimus (Compound) downregulates TFDP1 (Gene)
Temsirolimus (Compound) causes Febrile neutropenia (Side Effect)